First-in-human, phase I study of CBP-1008, a first-in-class bispecific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors.

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Clinical Oncology

Topics

Computer Science

Artificial Intelligence

Mathematics

Medicine

Cancer Oncology

Show all topics

DOI

10.1200/jco.2024.42.16_suppl.5556